Induction of apoptosis in colon cancer cells by a novel topoisomerase I inhibitor TopIn

Biochemical and Biophysical Research Communications

Volumn 409, Issue 1, 2011, Pages 75-81

  Bae, Soo Kyung ^a   Gwak, Jungsug ^b   Song, Im Sook ^c   Park, Hyung Soon ^d   Oh, Sangtaek ^b  

^a The Catholic University of Korea   (South Korea)

^b Kookmin University   (South Korea)

^c Inje University College of Medicine   (South Korea)

^d Probiond Co Ltd   (South Korea)

Author keywords

Apoptosis; Colon cancer; P53; Topoisomerase I inhibitor

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; 7 PHENYL 6H [1,2,5]OXADIAZOLO[3,4 E]INDOLE 3 OXIDE; BETA ACTIN; BIOCHEMICAL MARKER; BREAST CANCER RESISTANCE PROTEIN; CAMPTOTHECIN; CAMPTOTHECIN DERIVATIVE; CASPASE 3; CASPASE 7; CYCLIN DEPENDENT KINASE INHIBITOR 1; DNA FRAGMENT; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE INHIBITOR; MULTIDRUG RESISTANCE PROTEIN 1; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN P21; PROTEIN P53; SERINE; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL CYCLE ARREST; CELL PROLIFERATION; COLON CANCER; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME DEGRADATION; ENZYME INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; PRIORITY JOURNAL; PROTEIN DNA BINDING; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN STABILITY; TRANSCRIPTION REGULATION; UPREGULATION; WILD TYPE;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; ATP-BINDING CASSETTE TRANSPORTERS; CELL LINE; CELL LINE, TUMOR; CELL PROLIFERATION; COLONIC NEOPLASMS; DNA TOPOISOMERASES, TYPE I; DOGS; HUMANS; INDOLES; NEOPLASM PROTEINS; OXADIAZOLES; P-GLYCOPROTEIN; TOPOISOMERASE I INHIBITORS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 79956192536     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2011.04.108     Document Type: Article

References (36)

1. Gottlieb T.M., Oren M. p53 in growth control and neoplasia. Biochim. Biophys. Acta 1996, 1287:77-102.
2. A.J. Levine, M.E. Perry, A. Chang, A. Silver, D. Dittmer, M. Wu, D. Welsh, The 1993 Walter Hubert Lecture: the role of the p53 tumour-suppressor gene in tumorigenesis, Br. J. Cancer 69 (1994) 409-416.
3. Cordon-Cardo C., Sheinfeld J., Dalbagni G. Genetic studies and molecular markers of bladder cancer. Semin. Surg. Oncol. 1997, 13:319-327.
4. Dameron K.M., Volpert O.V., Tainsky M.A., Bouck N. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science 1994, 265:1582-1584.
5. Giaccia A.J., Kastan M.B. The complexity of p53 modulation: emerging patterns from divergent signals. Genes Dev. 1998, 12:2973-2983.
6. Hansen R., Oren M. p53; from inductive signal to cellular effect. Curr. Opin. Genet. Dev. 1997, 7:46-51.
7. Lane D.P., Hupp T.R. Drug discovery and p53. Drug Discov. Today 2003, 8:347-355.
8. Chen X., Ko L.J., Jayaraman L., Prives C. p53 levels, functional domains, and DNA damage determine the extent of the apoptotic response of tumor cells. Genes Dev. 1996, 10:2438-2451.
9. Kunze N., Yang G.C., Jiang Z.Y., Hameister H., Adolph S., Wiedorn K.H., Richter A., Knippers R. Localization of the active type I DNA topoisomerase gene on human chromosome 20q11.2-13.1, and two pseudogenes on chromosomes 1q23-24 and 22q11.2-13.1. Hum. Genet. 1989, 84:6-10.
10. Gupta M., Fujimori A., Pommier Y. Eukaryotic DNA topoisomerases I. Biochim. Biophys. Acta 1995, 1262:1-14.
11. Wang J.C. DNA topoisomerases. Annu. Rev. Biochem. 1996, 65:635-692.
12. Wang J.C. Cellular roles of DNA topoisomerases: a molecular perspective. Nat. Rev. Mol. Cell Biol. 2002, 3:430-440.
13. Ataka M., Ikeguchi M., Yamamoto M., Inoue M., Tanida T., Oka Shin-ichi, Katano K. Topoisomerase I protein expression and prognosis of patients with colorectal cancer. Yonago Acta Med. 2007, 50:81-87.
14. Braun M.S., Richman S.D., Quirke P., Daly C., Adlard J.W., Elliott F., Barrett J.H., Selby P., Meade A.M., Stephens R.J., Parmar M.K., Seymour M.T. Predictive biomarkers of chemotherapy efficacy in colorectal cancer: results from the UK MRC FOCUS trial. J. Clin. Oncol. 2008, 26:2690-2698.
15. Giovanella B.C., Stehlin J.S., Wall M.E., Wani M.C., Nicholas A.W., Liu L.F., Silber R., Potmesil M. DNA topoisomerase I-targeted chemotherapy of human colon cancer in xenografts. Science 1989, 246:1046-1048.
16. Saleem A., Dutta J., Malegaonkar D., Rasheed F., Rasheed Z., Rajendra R., Marshall H., Luo M., Li H., Rubin E.H. The topoisomerase I- and p53-binding protein topors is differentially expressed in normal and malignant human tissues and may function as a tumor suppressor. Oncogene 2004, 23:5293-5300.
17. Bakos E., Evers R., Szakács G., Tusnády G.E., Welker E., Szabó K., de Haas M., van Deemter L., Borst P., Váradi A., Sarkadi B. Functional multidrug resistance protein (MRP1) lacking the N-terminal transmembrane domain. J. Biol. Chem. 1998, 273:32167-32175.
18. Jonker J.W., Smit J.W., Brinkhuis R.F., Maliepaard M., Beijnen J.H., Schellens J.H., Schinkel A.H. Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan. J. Natl Cancer Inst. 2000, 92:1651-1656.
19. Foxwell B.M., Mackie A., Ling V., Ryffel B. Identification of the multidrug resistance-related P-glycoprotein as a cyclosporine binding protein. Mol. Pharmacol. 1989, 36:543-546.
20. Rabindran S.K., Ross D.D., Doyle L.A., Yang W., Greenberger L.M. Fumitremorgin C reverses multidrug resistance in cells transfected with the breast cancer resistance protein. Cancer Res. 2000, 60:47-50.
21. Shieh S.Y., Ikeda M., Taya Y., Prives C. DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2. Cell 1997, 91:325-334.
22. Park S.E., Min Y.K., Ha J.D., Kim B.T., Lee W.G. Novel small molecule induces p53-dependent apoptosis in human colon cancer cells. Biochem. Biophys. Res. Commun. 2007, 358:842-847.
23. Blagosklonny M.V. p53: an ubiquitous target of anticancer drugs. Int. J. Cancer 2002, 98:161-166.
24. Ting C.Y., Hsu C.T., Hsu H.T., Su J.S., Chen T.Y., Tarn W.Y., Kuo Y.H., Whang-Peng J., Liu L.F., Hwang J. Isodiospyrin as a novel human DNA topoisomerase I inhibitor. Biochem. Pharmacol. 2003, 66:1981-1991.
25. Choi M.K., Kim H., Han Y.H., Shim C.K., Song I.S. Involvement of Mrp2/MRP2 in the species different excretion route of benzylpenicillin between rat and human. Xenobiotica 2009, 39:171-181.
26. Song I.S., Choi M.K., Jin Q.R., Shim W.S., Shim C.K. Increased affinity to canalicular P-gp via formation of lipophilic ion-pair complexes with endogenous bile salts is associated with Mw threshold in hepatobiliary excretion of quaternary ammonium compounds. Pharm. Res. 2010, 27:823-831.
27. Pommier Y. Topoisomerase I inhibitors: camptothecins and beyond. Nat. Rev. Cancer 2006, 6:789-802.
28. Bodurka D.C., Levenback C., Wolf J.K., Gano J., Wharton J.T., Kavanagh J.J., Gershenson D.M. Phase II trial of irinotecan in patients with metastatic epithelial ovarian cancer or peritoneal cancer. J. Clin. Oncol. 2003, 21:291-297.
29. Koizumi F., Kitagawa M., Negishi T., Onda T., Matsumoto S., Hamaguchi T., Matsumura Y. Novel SN-38-incorporating polymeric micelles, NK012, eradicate vascular endothelial growth factor-secreting bulky tumors. Cancer Res. 2006, 66:10048-10056.
30. Hsiang Y.H., Lihou M.G., Liu L.F. Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin. Cancer Res. 1989, 49:5077-5082.
31. Tsao Y.P., D'Arpa P., Liu L.F. The involvement of active DNA synthesis in camptothecin-induced G2 arrest: altered regulation of p34cdc2/cyclin B. Cancer Res. 1992, 52:1823-1829.
32. Li T.K., Liu L.F. Tumor cell death induced by topoisomerase-targeting drugs. Annu. Rev. Pharmacol. Toxicol. 2001, 41:53-77.
33. Macdonald J.S., Benedetti J.K., Modiano M., Alberts D.S. Phase II evaluation of topotecan in patients with advanced colorectal cancer. A Southwest Oncology Group trial (SWOG 9241). Invest. New Drugs 1997, 15:357-359.
34. Conti J.A., Kemeny N.E., Saltz L.B., Huang Y., Tong W.P., Chou T.C., Sun M., Pulliam S., Gonzalez C. Irinotecan is an active agent in untreated patients with metastatic colorectal cancer. J. Clin. Oncol. 1996, 14:9-715.
35. Maliepaard M., van Gastelen M.A., Tohgo A., Hausheer F.H., van Waardenburg R.C., de Jong L.A., Pluim D., Beijnen J.H., Schellens J.H. Circumvention of breast cancer resistance protein (BCRP)-mediated resistance to camptothecins in vitro using non-substrate drugs or the BCRP inhibitor GF120918. Clin. Cancer Res. 2001, 7:935-941.
36. Yang C.H., Schneider E., Kuo M.L., Volk E.L., Rocchi E., Chen Y.C. BCRP/MXR/ABCP expression in topotecan-resistant human breast carcinoma cells. Biochem. Pharmacol. 2000, 60:831-837.